BamSEC and AlphaSense Join Forces
Learn More

RespireRx Pharmaceuticals Inc

Formerly OTC: RSPI
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 10 pages Alien Technology Transfer Nih Service Agreement
12/34/56
EX-10.1
from 8-K 14 pages Alien Technology Transfer Nih Service Agreement
12/34/56
EX-10.2
from 8-K 10 pages Nih Service Agreement
12/34/56
EX-10.1
from 8-K 14 pages Alien Technology Transfer Nih Service Agreement
12/34/56
EX-10.3
from 8-K 12 pages Warrant to Purchase Common Stock RespireRx Pharmaceuticals Inc
12/34/56
EX-10.2
from 8-K 4 pages Demand Promissory Note
12/34/56
EX-10.1
from 8-K 25 pages Demand Promissory Note and Warrant Purchase Agreement
12/34/56
EX-10.6
from 8-K 9 pages RespireRx Pharmaceuticals Inc Amended and Restated Convertible Note Due January 30, 2025
12/34/56
EX-10.5
from 8-K 9 pages RespireRx Pharmaceuticals Inc Amended and Restated Convertible Note Due January 30, 2025
12/34/56
EX-10.4
from 8-K 9 pages RespireRx Pharmaceuticals Inc Amended and Restated Convertible Note Due January 30, 2025
12/34/56
EX-10.3
from 8-K ~5 pages Debt Settlement Agreement
12/34/56
EX-10.2
from 8-K ~5 pages Debt Settlement Agreement
12/34/56
EX-10.1
from 8-K ~5 pages Debt Settlement Agreement
12/34/56
EX-10.2
from 8-K 4 pages Seven Life Sciences Client Contract Once You Agree the Contract, Please Either Sign in the Relevant Section and Scan Back to US via Email or Fax to 0203 88 77 374. You Can Also Sign Electronically and Return via Email if You Have the Facility and We Will Accept Your Email as Agreement
12/34/56
EX-10.1
from 8-K 10 pages RespireRx Pharmaceuticals Inc. (The “Company”) Is Pleased to Retain the Services of Ponto Ventures LLC (“Ponto”), Pursuant to Which Ponto Will Provide the Services of You, Will Clodfelter (“Clodfelter” or “Consultant”), as a Consultant to the Company on the Terms Described in This Agreement (“Agreement”) Effective as of the Date First Noted Above. 3. Compensation
12/34/56
EX-10.4
from 8-K 10 pages Master Intercompany Services Agreement
12/34/56
EX-10.3
from 8-K 41 pages Stock Transfer Agreement
12/34/56
EX-10.2
from 8-K 31 pages Sublicense Agreement
12/34/56
EX-10.1
from 8-K 7 pages License Agreement
12/34/56
EX-10.7
from 8-K 12 pages Warrant to Purchase Common Stock RespireRx Pharmaceuticals Inc. Warrant Number: Dpn-002 Initial Exercise Date: May 22, 2023
12/34/56